Venatorx Pharmaceuticals, Inc.
Publicly observedMalvern, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Malvern | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Venatorx Pharmaceuticals, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | MBBKNBU5DCC6 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Apr 2024Publicly observed
NIH SBIR/STTR award: Novel Cyclic Boronate Cell Wall Inhibitors Targeting Carbapenem-Resistant Acinetobacter baumannii
USD 1,000,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant7 Jun 2023Publicly observed
NIH SBIR/STTR award: Optimization of orally bioavailable inhibitors for the treatment of COVID-19 and other human coronavirus infections
USD 999,998.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.